Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 drug-drug interaction study of GS-4224 with CYP3A/P-gp/BCRP modulators and substrates in healthy volunteers
NL-OMON49788Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evixapodlin in Chronic Hepatitis B (CHB) (9 arms), sponsored by Gilead Sciences. Started Dec 2019; status: active, not recruiting.
02
Drugs
evixapodlin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON49788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49788.